Provention Bio, Inc. (NASDAQ:PRVB – Get Rating) – Analysts at Chardan Capital boosted their FY2022 earnings per share estimates for shares of Provention Bio in a research note issued on Monday, November 21st. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of ($1.30) per share for the year, up from their prior estimate of ($1.32). Chardan Capital currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Provention Bio’s current full-year earnings is ($1.67) per share. Chardan Capital also issued estimates for Provention Bio’s FY2023 earnings at ($1.28) EPS.
A number of other equities analysts have also recently issued reports on the company. Oppenheimer upped their target price on Provention Bio from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 18th. SVB Leerink upped their target price on Provention Bio from $16.00 to $19.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Jefferies Financial Group upped their target price on Provention Bio from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, November 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Provention Bio presently has a consensus rating of “Buy” and a consensus target price of $21.40.
Provention Bio Price Performance
Institutional Investors Weigh In On Provention Bio
Institutional investors have recently made changes to their positions in the stock. Bioimpact Capital LLC bought a new stake in shares of Provention Bio in the 2nd quarter valued at about $2,370,000. Rice Hall James & Associates LLC grew its position in shares of Provention Bio by 2.6% in the 2nd quarter. Rice Hall James & Associates LLC now owns 225,785 shares of the company’s stock valued at $903,000 after buying an additional 5,720 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Provention Bio in the 1st quarter valued at about $49,000. Sigma Planning Corp grew its position in shares of Provention Bio by 22.3% in the 2nd quarter. Sigma Planning Corp now owns 153,690 shares of the company’s stock valued at $615,000 after buying an additional 28,070 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new stake in shares of Provention Bio in the 2nd quarter valued at about $41,000. Institutional investors own 37.39% of the company’s stock.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.
- Get a free copy of the StockNews.com research report on Provention Bio (PRVB)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.